The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia

ABSTRACT

The CDKN2A/B genes in the 9p21 chromosomal region are frequently involved in human cancer, including pediatric acute lymphoblastic leukemia (ALL). These genes encode 3 proteins that belong to the RB1 and TP53 pathways and act as tumor suppressors by regulating the G1/S checkpoint of the cell cycle. The prognostic value of deletions in the CDKN2A/B locus in ALL is controversial in part due to the limitations of the methodologies used. Further studies with advanced technologies are needed for elucidation. Future studies would also highlight whether CDK4/CDK6 selective inhibitors might be useful therapies for children with these genetic aberrations.

KEYWORDS:

• CDK4/CDK6 inhibitors
• CDKN2A gene
• CDKN2B gene
• deletions
• pediatric acute lymphoblastic leukemia
• prognosis

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by the National Health Service of Spain, Instituto de Salud Carlos III (ISCIII), FONDOS FEDER grant (FIS) EC11-057 to Antonio Pérez Martínez and a Fundacion Unoentrecienmil to Pilar Carrasco Salas.